In vitro bioequivalence study of nine brands of artesunate tablets marketed in Nigeria

Journal of Vector Borne Diseases

Volumn 45, Issue 1, 2008, Pages 60-65

  Esimone, C O ^a   Okoye, F B C ^a   Onah, B U ^a   Nworu, C S ^a   Omeje, E O ^a  

^a UNIVERSITY OF NIGERIA   (Nigeria)

Author keywords

Artesunate tablets; Bioequivalence; Disintegration time; Hardness; In vitro dissolution

Indexed keywords

ARTESUNATE;

ARTICLE; BIOEQUIVALENCE; DRUG FORMULATION; DRUG SOLUBILITY; IN VITRO STUDY; NIGERIA; QUALITY CONTROL; TABLET DISINTEGRATION TIME; TABLET HARDNESS;

ANTIMALARIALS; ARTEMISININS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; HUMANS; MODELS, BIOLOGICAL; NIGERIA; SESQUITERPENES; SOLUBILITY; TABLETS; THERAPEUTIC EQUIVALENCY;

EID: 40449105524     PISSN: 09729062     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Facer CA, Tanner M. Clinical trials of malaria vaccines: progress and prospects. Adv Parasitol 1997; 39: 1-68.
2. Hien TT, White NJ. Qinghaosu. Lancet 1993; 341: 603-8.
3. Nosten F, Luxemburger C, ter Kuile FO, Woodrow C, Pa Eh J, Chongsuphajaisiddhi T, et al. Treatment of multidrug resistant falciparum malaria with a 3-day artesunate-mefloquine combination. J Infect Dis 1994; 170: 971-7.
4. Na-Bangchang K, Karbwang J, Congpoung K, Thanavibul A, Ubalee R. Pharmacokinetic and bioequivalence evaluation of two generic formulations of oral artesunate. Eur J Clin Pharmacol 1998; 53: 375-6.
5. White, NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 1997; 41: 1413-22.
6. Barradell LB, Fitton A. Artesunate: a review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs 1995; 50: 714-41.
7. Bethell DB, Teja-Isavadharm P, Phuong CX, Thuy PT, Mai TT, Thuy TT, et al. Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 1997; 91: 195-8.
8. Newton P, Suputtamongkol Y, Teja-isavadharm P, Pukrittayakamee S, Navaratnam V Bates I, et al. Antimalarial bioavailability and disposition of artesunate in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44(4): 972-7.
9. Osadebe PO, Akabogu IC. Assessment of quality control parameters and interchangeability of multisourced metformin HCl tablets marketed in Nigeria. Boll Chim Farm 2004; 143(4): 170-3.
10. Osadebe PO, Esimone CO, Akabogu IC. An empirical assessment of the possibility of interchangeability between multisource ciprofloxacin hydrochloride tablets marketed in Nigeria. Boll Chim Farm 2003; 142(8): 352-6.
11. Osadebe PO, Esimone CO. Qualitative and quantitative evaluation of multisource piroxicam capsules available in Nigeria. Bio Res 2003; 1(2): 101-10.
12. Note for guidance on the investigation of bioavailability and bioequivalence. The European agency for the evaluation of medicinal products (Evaluation of Medicines for Human Use). London: Committee for Proprietary Medicinal Products 2001.
13. United States Pharmacopoeia XX. Easton: Mack Publishing Co. 1980; p. 958-9.
14. Ofoefule SI, Orisakwe OE, Ibezim EC, Esimone CO. Mechanisms of nifedipine release from sustained release tablets formulated with some polymeric materials. Boll Chim Farm 1998; 137: 223-7.
15. Chow CS, Liu JP. Design and analysis of bioavailability and bioequivalence studies. New York: Marcel Dekker 1992; p. 1-2.
16. British Pharmacopoeia. London: The Stationery Office, 2001; p. 1183.
17. Proudfoot SG. Factors Influencing bioavailability and drug absorption from the gastrointestinal tract. In Aulton Mr., editor. Pharmacokinetics: The Science of dosage forms design, I edn. London: Churchill Linguistic 1988; p. 135.